Currently Available Treatments:

- Specific ECM-destroying MMP inhibitors: None; Cell growth stimulators: None (Growth factors are proteins & are destroyed by MMPs). No treatment for 30 million patients in Europe alone!!
- Symptomatic: Hydrogels, hydrating bandages, antiseptics, in vitro bioengineered skin…

VITROBIO’s Completely NEW Therapeutic Approach: Specific MMP antagonists in a natural hydrating & antiseptic solution.

Employing in vitro epidermis models, Vitrobio identified ECM-destroying MMPs (Matrix Metallo-Proteinases). MMPs are proteins and certain plant procyanidins (PCDs), which are very big & inert natural plant molecules, have a strong affinity for specific proteins. Therefore, we identified specific MMP-antagonist PCDs.

These PCDs were incorporated into a glycerol-based viscous liquid (VB-Gly), 18 times more osmotically active than sea water yet NON-IRRITANT (International patent 1997: PCT/FR99/01340). A new patent on a filmogen VB-Gly solution was recently filed (N° PCT/E02013/061835). When applied as a thin layer on the wound surface, ANTISCAR immediately forms a film & creates a strong outward flow of hypotonic liquid, instantly detaching all the contaminants & PCD-MMP conjugates from the wound surface. The wound-cleaning function of MMPs is replaced by the long-lasting, outward flow of hypotonic liquid induced by VB-Gly, which equally protects the wound surface & keeps it hydrated.

Product Presentation: Viscous Solution in 50mL Tube.

Directions: Topical application to form a film over the wound surface, 2-3 times per day until complete recovery.

Regulatory Status: Due to the purely mechanical topical filmogen activity without any pharmacological, biological, metabolic or immunological interaction with the cellular structure: Class Ia Medical Device in Europe.

Contraindications: Not to be used in conjunction with any cell-unfriendly treatment (antiseptics, chemicals)

Side Effects: None


Marketing Status: Ready to launch

Launched or under launch (2012-2016): Australia, Colombia, Djibouti, Dubai, Egypt, Finland, France, Israel, Malaysia, Middle east, New Zealand, South Africa, South Korea, Tunisia…